SCHEMBL6580283

SCHEMBL6580283

CCCCCc1c(-c2ccc3cc(OCC(=O)O)ccc3c2)oc2ccccc12

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 5/20 0.57
LMNA P02545 1/20 0.51
KDM4E B2RXH2 4/20 0.51
ALDH1A1 P00352 2/20 0.48
PPARG P37231 1/20 0.47
PPARA Q07869 1/20 0.47
PTPN7 P35236 1/20 0.46
TSHR P16473 1/20 0.46
PSEN1 P49768 5/20 0.45
PSEN2 P49810 5/20 0.45
APH1B Q8WW43 5/20 0.45
NCSTN Q92542 5/20 0.45
APH1A Q96BI3 5/20 0.45
PSENEN Q9NZ42 5/20 0.45
THRA P10827 2/20 0.45
THRB P10828 2/20 0.45
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6583740 0.90 KDM4E (0.53) PTPN1KDM4EALDH1A1PPARGPPARA
SCHEMBL6582980 0.85 PTPN1 (0.66) PTPN1KDM4EALDH1A1TSHRTHRA
SCHEMBL6585145 0.84 CNR1 (0.47) KDM4EALDH1A1TSHRGAA
SCHEMBL6579471 0.83 LMNA (0.53) PTPN1LMNAKDM4EALDH1A1PTPN7
SCHEMBL6581416 0.83 PSEN1 (0.44) PTPN1KDM4EALDH1A1TSHRPSEN1
SCHEMBL6582140 0.81 PTPN1 (0.57) PTPN1KDM4EALDH1A1PPARGGAA
SCHEMBL6580236 0.78 LMNA (0.56) LMNAKDM4EALDH1A1PTPN7THRA
SCHEMBL6579684 0.78 PTPN1 (0.38) PTPN1KDM4E
SCHEMBL6581447 0.77 LMNA (0.55) PTPN1LMNAKDM4EALDH1A1PTPN7
SCHEMBL6583913 0.76 PTPN1 (0.55) PTPN1LMNAKDM4EALDH1A1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1401822-A1 NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) Wyeth (US) 2004-03-31 EP claimed
US-6599925-B2 Cardiovascular disorders; anticancer agents WYETH 2003-07-29 US claimed
US-20030018067-A1 Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) WYETH 2003-01-23 US claimed
WO-2003000671-A1 NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) WYETH (US) 2003-01-03 WO claimed
EP-1401822-A1 NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) Wyeth (US) 2004-03-31 EP disclosed
US-6599925-B2 Cardiovascular disorders; anticancer agents WYETH 2003-07-29 US disclosed
US-20030018067-A1 Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) WYETH 2003-01-23 US disclosed
WO-2003000671-A1 NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) WYETH (US) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018067-A1 Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) F2R, SERPINE1, SERPINC1 PTPN1 1287/4885LMNA 903/4885KDM4E 4021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.